KANO CRACKDOWN: Task Force Shuts Pharmaceutical Firm Over ₦900m Pregabalin Haul
The Kano State Multi-Agency Taskforce on Drug Abuse and Illicit Trafficking has shut down a pharmaceutical company following the discovery of over 3.1 million tablets of Pregabalin, a controlled medication allegedly being illegally distributed across the state.
The seized drugs, estimated to be worth more than ₦900 million, were discovered during an operation at the company’s premises in a residential neighbourhood of Sabon Gari, Kano.
The chairman of the task force, Muhuyi Magaji, disclosed the development on Saturday while conducting journalists around the facility. He said operatives recovered approximately 3,180,000 tablets of Pregabalin suspected to have been stored for illegal distribution.
Magaji further revealed that the agency had arrested 1,760 suspects and secured 890 convictions as part of its ongoing campaign against drug abuse, illicit trafficking and related criminal activities in the state.
He, however, expressed concern over what he described as the alleged involvement of some licensed pharmaceutical companies in sustaining the illegal supply of controlled medicines, despite ongoing efforts by law enforcement agencies to curb drug abuse.
The task force chairman also raised allegations against some officials of the Pharmaceutical Council of Nigeria (PCN) and the National Agency for Food and Drug Administration and Control (NAFDAC) in Kano, accusing them of allegedly facilitating the circulation of Pregabalin and other controlled drugs.
According to Magaji, licences reportedly issued by certain regulatory authorities may have contributed to the movement of restricted medications into the illegal drug market, despite their limited availability through legitimate pharmaceutical outlets.
He identified Pregabalin as one of the most widely abused substances in Kano, claiming that eight out of every 10 suspected drug users arrested by the task force were either found with the medication or admitted to consuming it.
Magaji also questioned the issuance of import licences for Pregabalin following its classification as a controlled drug by NAFDAC on September 14, 2026.
He specifically cited an import licence allegedly granted to a pharmaceutical company in Kano on October 23, 2026, insisting that the circumstances surrounding the approval required thorough investigation in view of the growing abuse of the drug.
The task force chairman further alleged that preliminary investigations indicated that the company’s owner had established another business entity allegedly being used to disguise the illegal distribution of controlled medicines through concealed networks.
He also questioned how the facility secured regulatory approval, particularly in relation to applicable land-use requirements for its location within a residential neighbourhood.
Magaji went on to allege that certain PCN officials had links with suspected illegal drug distribution networks and were allegedly frustrating efforts to dismantle the operations because of personal interests.
Expressing concern over what he described as the apparent protection of drug suppliers, the task force chairman maintained that tackling drug abuse would remain difficult if attention was focused primarily on users while those allegedly responsible for supplying the substances continued to operate.
He stressed the need for accountability among regulatory authorities, arguing that enforcement efforts must target both drug consumers and the individuals or organisations responsible for making controlled substances available through illegal channels.
The allegations against regulatory officials and the pharmaceutical company have not been independently established in the information provided.

Comments
0 comments